The British Journal of Psychiatry (2006) 189: 184-185. doi: 10.1192/bjp.bp.105.017079
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Paton, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paton, C.

SHORT REPORTS

Generic clozapine: outcomes after switching formulations

Carol Paton, BSc, DipClinPharm, MRPharmS, MCMHP

Oxleas NHS Trust, Pinewood House, Pinewood Place, Dartford, Kent DA2 7WG, UK. Tel: +44 (0) 1322 55 2999; email: carol.paton{at}oxleas.nhs.uk

Declaration of interest None.

Summary Two generic preparations of clozapine have been licensed in the UK. The bioequivalence of these products compared with Clozaril® has not been unequivocally demonstrated. Clinical equivalence has also been questioned. The objective of this study was to determine clinical outcomes for all patients switched from Clozaril® to a generic formulation in one mental health service. We examined dosage data and Clinical Global Impression (CGI) of Severity of Illness scores for 337 patients before and after the switch and CGI change scores after the switch. There was no evidence of clinical deterioration or need to use higher dosages. Generic clozapine is not inferior to Clozaril®.